VERU News - Candlesense

Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress

--Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal s...

What risks remain that could offset the positive data, such as safety signals in larger populations or competitive trial results? How could the Phase 2b results influence partnership or licensing discussions with larger pharma companies? What is the expected impact on VERU’s cash burn and financing needs given the need to fund Phase 3 development?

Clinical trials

9 days ago

Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru’s Enobosarm, Utilizing Laxxon’s SPID®-Technology

NEW YORK--(BUSINESS WIRE)--Laxxon - Veru Announcement

Could this development trigger any changes in short‑selling activity or institutional positioning in VERU? What is the anticipated impact on VERU's cash burn and financing needs given the upcoming clinical and regulatory expenses? How could this milestone influence analyst coverage and consensus estimates for VERU?

Product development

9 days ago

Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study

MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic ...

What implications does this have for Veru’s overall pipeline prioritization and allocation of R&D resources? Are there any upcoming FDA meetings, advisory committee reviews, or regulatory milestones tied to this formulation? How might the announcement affect Veru’s cash burn rate and the need for additional financing or equity raises?

Clinical

10 days ago